IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process
Points To ‘Limited Value’ Of Efficacy Data; Urges Renewed Education Efforts
The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.
